DOI QR코드

DOI QR Code

miR-153 Silencing Induces Apoptosis in the MDA-MB-231 Breast Cancer Cell Line

  • Anaya-Ruiz, Maricruz (Laboratory of Cellular Biology, Centro de Investigacion Biomedica de Oriente, Instituto Mexicano del Seguro Social) ;
  • Cebada, Jorge (Escuela de Biologia, Benemerita Universidad Autonoma de Puebla) ;
  • Delgado-Lopez, Guadalupe (Laboratory of Cellular Biology, Centro de Investigacion Biomedica de Oriente, Instituto Mexicano del Seguro Social) ;
  • Sanchez-Vazquez, Maria Luisa (Laboratory of Reproductive Biology, Centro de Investigacion Biomedica de Oriente, Instituto Mexicano del Seguro Social) ;
  • Perez-Santos, Jose Luis Martin (Vice-rectory of Research and Postgraduate Studies, Benemerita Universidad Autonoma de Puebla)
  • Published : 2013.05.30

Abstract

MicroRNAs (miRNAs) are small, non-coding RNAs (18-25 nucleotides) that post-transcriptionally modulate gene expression by negatively regulating the stability or translational efficiency of their target mRNAs. In this context, the present study aimed to evaluate the in vitro effects of miR-153 inhibition in the breast carcinoma cell line MDA-MB-231. Forty-eight hours after MDA-MB-231 cells were transfected with the miR-153 inhibitor, an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was utilized to determine the effects of miR-153 on cell viability. Flow cytometry analysis and assessment of caspase 3/7 activity were adopted to determine whether miR-153 affects the proliferation rates and apoptosis levels of MDA-MB-231 cells. Our results showed that silencing of miR-153 significantly inhibited growth when compared to controls at 48 hours, reducing proliferation by 37.6%, and inducing apoptosis. Further studies are necessary to corroborate our findings and examine the potential use of this microRNA in future diagnostic and therapeutic interventions.

Keywords

Breast cancer;microRNA;apoptosis;triple negative;miR-153 silencing

References

  1. Connolly R, Stearns V (2012). Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia, 17, 191-204. https://doi.org/10.1007/s10911-012-9263-3
  2. Haghighat S, Akbari M, Ghaffari S (2012). Standardized breast cancer mortality rate compared to the general female population of Iran. Asian Pac J Cancer Prev, 13, 5525-8. https://doi.org/10.7314/APJCP.2012.13.11.5525
  3. Harquail J, Benzina S, Robichaud GA (2012). MicroRNAs and breast cancer malignancy: an overview of miRNA-regulated cancer processes leading to metastasis. Cancer Biomark, 11, 269-80.
  4. Huang Y, Nayak S, Jankowitz R, et al (2011). Epigenetics in breast cancer: what's new? Breast Cancer Res, 13, 225-35. https://doi.org/10.1186/bcr2925
  5. Kala R, Peek GW, Hardy TM, et al (2013). MicroRNAs: an emerging science in cancer epigenetics. J Clin Bioinforma, 16, 6-13.
  6. Kim TH, Kim YK, Kwon Y, et al (2010). Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology, 57, 734-43. https://doi.org/10.1111/j.1365-2559.2010.03686.x
  7. Lages E, Ipas H, Guttin A, et al (2012). MicroRNAs: molecular features and role in cancer. Front Biosci, 17, 2508-40. https://doi.org/10.2741/4068
  8. Lee S, Vasudevan S (2013). Post-transcriptional stimulation of gene expression by microRNAs. Adv Exp Med Biol, 768, 97-126. https://doi.org/10.1007/978-1-4614-5107-5_7
  9. Li S, Meng H, Zhou F, et al (2013). MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation. Pathol Res Pract, 209, 179-83. https://doi.org/10.1016/j.prp.2012.12.002
  10. Lindstrom LS, Karlsson E, Wilking UM, et al (2012). Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol, 30, 2601-8. https://doi.org/10.1200/JCO.2011.37.2482
  11. Mar-Aguilar F, Luna-Aguirre CM, Moreno-Rocha JC, et al (2013). Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue. Asia Pac J Clin Oncol, 9, 53-9. https://doi.org/10.1111/j.1743-7563.2012.01548.x
  12. Ozgun A, Karagoz B, Bilgi O, et al (2013). MicroRNA-21 as an Indicator of Aggressive Phenotype in Breast Cancer. Onkologie, 36, 115-8. https://doi.org/10.1159/000348678
  13. Parpart S, Wang XW (2013). microRNA Regulation and Its Consequences in Cancer. Curr Pathobiol Rep, 1, 71-9. https://doi.org/10.1007/s40139-012-0002-7
  14. Siegel R, Naishadham D, and Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  15. Singh R, Mo YY (2013). Role of microRNAs in breast cancer. Cancer Biol Ther, 14, 201-12. https://doi.org/10.4161/cbt.23296
  16. Tang J, Ahmad A, Sarkar FH (2012). The Role of MicroRNAs in Breast Cancer Migration. In J Mol Sci, 13, 13414-37. https://doi.org/10.3390/ijms131013414
  17. Wu Z, He B, He J, et al (2013). Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer. Prostate, 73, 596-604. https://doi.org/10.1002/pros.22600
  18. Xu J, Liao X, Wong C (2010). Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG. Int J Cancer, 126, 1029-35.
  19. Xu J, Liao X, Lu N, et al (2011). Chromatin-modifying drugs induce miRNA-153 expression to suppress Irs-2 in glioblastoma cell lines. Int J Cancer, 129, 2527-31. https://doi.org/10.1002/ijc.25917
  20. Xu Q, Sun Q, Zhang J, et al (2013). Downregulation of miR-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer. Carcinogenesis, 34, 539-49. https://doi.org/10.1093/carcin/bgs374
  21. Yang L, Sun TT, Wang N (2012). The incidence and mortality trends of female breast cancer in Beijing, China: between 2004 and 2008. Zhonghua Yu Fang Yi Xue Za Zhi, 46, 1009-14.
  22. Zhao S, Deng Y, Liu Y, et al (2013). MicroRNA-153 is tumor suppressive in glioblastoma stem cells. Mol Biol Rep, 40, 2789-98. https://doi.org/10.1007/s11033-012-2278-4

Cited by

  1. Down-regulation of miRNA-452 is Associated with Adriamycin-resistance in Breast Cancer Cells vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5137
  2. Role of MicroRNAs in the Warburg Effect and Mitochondrial Metabolism in Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7015
  3. Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs vol.31, pp.6, 2014, https://doi.org/10.1007/s10585-014-9664-3
  4. The role of microRNAs in human breast cancer progression vol.35, pp.7, 2014, https://doi.org/10.1007/s13277-014-2202-8
  5. MicroRNA-153 Inhibits Osteosarcoma Cells Proliferation and Invasion by Targeting TGF-β2 vol.10, pp.3, 2015, https://doi.org/10.1371/journal.pone.0119225
  6. MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma vol.34, pp.2, 2015, https://doi.org/10.3892/or.2015.4051
  7. The Ia-2β intronic miRNA, miR-153, is a negative regulator of insulin and dopamine secretion through its effect on the Cacna1c gene in mice vol.58, pp.10, 2015, https://doi.org/10.1007/s00125-015-3683-8
  8. miRNAs and their role in the correlation between schizophrenia and cancer vol.14, pp.6, 2016, https://doi.org/10.3892/mmr.2016.5853
  9. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers vol.38, pp.6, 2015, https://doi.org/10.1007/s13402-015-0239-3
  10. In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer vol.19, pp.3, 2018, https://doi.org/10.3390/ijms19030910